Johnson & Johnson (JNJ) is due to report earnings before the opening bell on October 18, 2011.
Overview
JNJ trades an average of 11.8 million shares per day.
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
I am bullish with Johnson & Johnson, and believe it will beat the estimates.
52-Week High: $68.05
52-Week Low: $57.50
Book Value: $22.67
Float Short: 1.96%
On average, 16 analysts are expecting a drop of $-0.07 in earnings per share compared to last quarter's results of $1.28. A beat of $1.21 per share will top the estimated per share earnings. Analyst estimates range between $1.16 and $1.30 per share.
The current trailing twelve months (ttm) P/E ratio is 15.4 The forward P/E ratio is 12.9. In the last month, the stock has increased in price 0.94%, with a one-year change of 1.64%. Compared to the S&P 500, the year-to-date difference is 8.36%.
For the same fiscal period year-over-year, revenue has declined to $61.59 billion for 2010 vs. $61.90 billion for 2009. The bottom line has rising earnings year-over-year of $13.33 billion for 2010 vs. $12.27 billion for 2009. The company's earnings before income and taxes are rising, with an EBIT year-over-year of $16.53 billion for 2010 vs. $15.59 billion for 2009.
Gross reported revenue compared to the mean estimate (rounded).
| Fiscal Quarter Ending Month-Year | Revenue Estimates | Actual | $ Difference | Difference % |
|---|---|---|---|---|
| Jun-11 | $ 16.23 B | $ 16.60 B | $ 362.90 M | 2.24% |
| Mar-11 | $ 15.83 B | $ 16.17 B | $ 341.50 M | 2.16% |
| Dec-10 | $ 16.01 B | $ 15.64 B | $ -370.70 M | -2.31% |
| Sep-10 | $ 15.18 B | $ 14.98 B | $ -201.00 M | -1.32% |
| Jun-10 | $ 15.63 B | $ 15.33 B | $ -303.70 M | -1.94% |
Differences are rounded.
Some one-time items are often excluded in reported EPS.
Reported earnings per share compared to the mean estimate. Differences are rounded.
Forest Laboratories, Inc. (FRX) is due to report earnings before the opening bell on October 18, 2011.
Overview
FRX trades an average of 3.3 million shares per day.
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products. The company was founded in 1956 and is based in New York, New York.
52-Week High: $40.52
52-Week Low: $29.26
Book Value: $19.25
Float Short: 9.72%
On average, 21 analysts are expecting a drop of $-0.06 in earnings per share compared to last quarter's results of $1.04. The estimated mean earnings are $0.98 per share. Analyst estimates range between $0.92 and $1.09 per share.
The stock has fallen in price -1.80%, with a one year change of -1.20%. Compared to the S&P 500, the year to date difference is 5.02%.
Investors have been rewarded with an increase in year-over-year revenue. Revenue reported was $4.42 billion for 2011 vs. $4.19 billion for 2010. The bottom line has rising earnings year-over-year of $1.05 billion for 2011 vs. $682.38 million for 2010. The company's earnings before income and taxes are rising, with an EBIT year-over-year of $1.34 billion for 2011 vs. $950.69 million for 2010.
Gross reported revenue compared to the mean estimate (rounded).
| Fiscal Quarter Ending Month-Year | Revenue Estimates | Actual | $ Difference | Difference % |
|---|---|---|---|---|
| Jun-11 | $ 1.12 B | $ 1.15 B | $ 33.05 M | 2.95% |
| Mar-11 | $ 1.11 B | $ 1.14 B | $ 28.86 M | 2.6% |
| Dec-10 | $ 1.10 B | $ 1.13 B | $ 26.36 M | 2.4% |
| Sep-10 | $ 1.07 B | $ 1.09 B | $ 13.99 M | 1.3% |
| Jun-10 | $ 1.06 B | $ 1.07 B | $ 6.39 M | 0.6% |
Differences are rounded.
Some one-time items are often excluded in reported EPS.
Reported earnings per share compared to the mean estimate. Differences are rounded.
I use a proprietary blend of technical analysis, financial crowd behavior, and fundamentals in my short-term trades, and while not totally the same in longer swing trades to investments, the concepts used are similar. You may want to use this article as a starting point of your own research with your financial planner. I use Seeking Alpha, Edgar Online, and Yahoo Finance for most of my data. I use the confirmed symbols from earnings.com that I believe to be of the most interest.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
No comments:
Post a Comment